Aileron Therapeutics Appoints Veterans of Life Sciences Industry and Wall Street to its BOD; Nobel Laureate and Venerated Drug Developers Join Company’s SAB

Aileron Therapeutics, Inc., a biopharmaceutical company that has defined a new class of drugs called Stapled Peptides, today announced the appointments of three veterans of the life sciences industry and Wall Street to its Board of Directors (BOD), as well as three internationally renowned research professionals to its Scientific Advisory Board (SAB). These advisors will serve as a strategic asset to Aileron as the company continues to advance several drug development programs utilizing its Stapled Peptide™ technology.

Back to news